MAM
JK Technosoft Ltd is organizing live webinar on ‘Chatbot at work in Just 5-days’ to support business continuity amidst COVID-19
Due to the enforced lockdown, businesses are struggling big-time especially those involved with customer service like e-commerce, Retail, Healthcare, Travel, Insurance, Logistics etc. According to a report by Deloitte India published in 2019, the Service sector accumulates to 61.5% of India’s GDP, which is fairly higher than China (52%). The service sector has a huge reliance on the customer service/support industry to carry its operations. With the lockdown in place, the customer service teams, through trying their best to adapt themselves to work remotely and with less resources, are still far away to adapt to the current scenario. Customers on the other end are facing difficulty in reaching out to get the required support they need resulting in long queues of support requests, unanswered calls or emails, and delays in resolving customer queries.
Today when the companies are opening up to try new-age technologies to make pace with the fast-moving world, involvement of technology in the form of AI-enabled Chatbots can be the new means to support various industries in this crucial period in which the whole nation is engulfed in. Chatbots can help in ‘Optimising Customer Support Function to Reduce Impact of Peak Customer Queries’.
Realizing the situation, JK Technosoft’s Digital & Innovation team is working round-the-clock to deploy Chatbot service in just 5 days. Chatbots provide an excellent way to ramp up customer resolutions quickly and can help companies get the resources they need to keep their standards of customer service high.
The webinar will have Mr. Praveen Kumar, Vice President, Digital & Innovation, JK Technosoft Ltd and Mr. Shankar Kamra, Technical Lead, JK Technosoft Ltd. as the lead speakers. The webinar will go live on Tuesday, 14th April 2020.
Commenting on the webinar, Mr. Praveen Kumar, Vice President, Digital & Innovation, JK Technosoft Ltd. said, “In light of the current scenario in the country, we wanted to ensure people still had the opportunity to enhance their knowledge and at the same time help businesses to optimise their operations. We want to support people in every way possible at this challenging time.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
